Tag: Bureau of Competition

Displaying 1 - 20 of 419 results.

Pages

Filtering by content type: Press Release

Testifying on behalf of the Federal Trade Commission before a subcommittee of the U.S. House of Representatives’ Committee on Energy and Commerce, Tara Koslov, Deputy Director of the FTC’s Office of Policy Planning, described the state of competition in the pet medications industry, as well as the...
A company that supplies some of the world’s largest medical device makers with a high-performance polymer used to make spinal and other medical implants has agreed to settle Federal Trade Commission charges that it violated federal antitrust law by using long-term exclusive contracts to maintain...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive. Under the order, first announced in February 2016, the companies are required to
Star Pipe Products, Ltd., a supplier of ductile iron pipe fittings, will pay $120,000 in civil penalties to resolve Federal Trade Commission allegations that it violated a 2012 Commission order prohibiting it from sharing competitively sensitive information. It also has agreed to an order...
Federal Trade Commission Chairwoman Edith Ramirez and Assistant Attorney General Bill Baer of the U.S. Department of Justice’s Antitrust Division participated in high level bilateral meetings with officials responsible for China’s three anti-monopoly agencies – National Development and Reform...
The Federal Trade Commission and the Department of Justice today issued a joint statement reaffirming the importance of preserving competition in the defense industry.
Following a public comment period, the Federal Trade Commission has approved an application by Pfizer Inc. to modify the FTC’s January 2010 final order, which settled the FTC’s competition concerns arising from Pfizer’s 2009 acquisition of Wyeth.
Federal Trade Commission Chairwoman Edith Ramirez released the FTC’s 2015 Annual Highlights today, featuring some of the agency’s key efforts to benefit consumers and promote competition over the past calendar year.
The Federal Trade Commission has approved a modified final order settling charges that Hikma Pharmaceuticals PLC’s acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. was anticompetitive.
The Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm. Following...
Federal Trade Commission staff submitted a comment, as public testimony, to the Alaska legislature on proposed legislation that would allow licensed Alaska physicians located out-of-state to provide telehealth services in the same manner as in-state physicians. 
Federal Trade Commission staff submitted a comment on the competitive implications of proposed legislation that would license and regulate denturists within Kentucky.  Denturists are trained to make and fit removable partial and full dentures. Currently, Kentuckians who need dentures must obtain...
Federal Trade Commission Chairwoman Edith Ramirez issued the following statement regarding the Supreme Court’s denial of certiorari in McWane Inc. v. FTC. The Court declined to review an April 2015 decision of the Eleventh Circuit upholding a Commission cease and desist order against McWane for...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that national kidney-dialysis chain U.S. Renal Care, Inc.’s $640 million acquisition of competitor DSI Renal from DSI Renal’s ultimate parent company, Dialysis Parent, LLC, would be...
The Federal Trade Commission filed an amicus brief with the U.S. Court of Appeals for the Third Circuit urging the court to correct four legal errors in a district court’s antitrust analysis of an alleged reverse-payment agreement involving brand-name pharmaceutical company GlaxoSmithKline and...
Testifying on behalf of the Federal Trade Commission before the U.S. Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, Chairwoman Edith Ramirez outlined how effective antitrust enforcement benefits both consumers and businesses by preventing mergers and business...
Drug manufacturer Hikma Pharmaceuticals PLC will sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive.
The Federal Trade Commission has approved a modified final order settling charges that Mylan N.V.’s proposed hostile takeover of Perrigo Company plc would harm competition. Because Mylan failed to obtain the required threshold of Perrigo shares to succeed in its unsolicited offer, Mylan has...
The Federal Trade Commission will require generic drug marketer Hikma Pharmaceuticals PLC to divest its rights and interests in five generic injectable pharmaceuticals, as part of a settlement resolving charges that Hikma’s $5 million acquisition of the rights to various drug products and related...
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC will sell the rights and assets for two generic drugs, one used to treat bacterial infections and the other to treat ulcerative colitis, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would...

Pages